Therefore, interventions to reduce or reverse overweight and obesity could improve both symptoms and long-term outcomes of patients with lupus or systemic inflammation, and if this is not achievable then targeting TLR7 is expected to have beneficial effects both for SLE and for metabolic inflammation, especially in certain genetically predisposed individuals. The gene discussed is TLR7; the disease is systemic lupus erythematosus.